Generics in the United Kingdom

Date: January 4, 2016
Pages: 34
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G3D4FC04467EN
Leaflet:

Download PDF Leaflet

Generics in the United Kingdom
INTRODUCTION

Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Kingdom generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

HIGHLIGHTS
  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The UK generics market is expected to generate total revenues of $8.2bn in 2015, representing a compound annual growth rate (CAGR) of 9.4% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 85.8 % of total pharma volume in 2015.
  • The UK healthcare market is reliant on generics to provide cost savings, especially in recent years as healthcare spending has been cut. According to the British Generic Manufacturers Association (BGMA), the average cost to the NHS of a generic medicine is £3.79. Comparatively, the average cost of a branded medicine is £19.73. The reliance on cost-effective generic medicines should see the market continue to grow.
FEATURES
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United Kingdom
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United Kingdom
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the United Kingdom economy
KEY QUESTIONS ANSWERED
  • What was the size of the United Kingdom generics market by value in 2015?
  • What will be the size of the United Kingdom generics market in 2020?
  • What factors are affecting the strength of competition in the United Kingdom generics market?
  • How has the market performed over the last five years?
  • How large is the United Kingdom’s generics market in relation to its regional counterparts?
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Allergan plc
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country Data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: United Kingdom generics market value: $ billion, 2011–15(e)
Table 2: United Kingdom generics market volume: % of total pharma volume, 2011–15(e)
Table 3: United Kingdom generics market geography segmentation: $ billion, 2015(e)
Table 4: United Kingdom generics market value forecast: $ billion, 2015–20
Table 5: United Kingdom generics market volume forecast: % of total pharma volume, 2015–20
Table 6: Allergan plc: key facts
Table 7: Allergan plc: key financials ($)
Table 8: Allergan plc: key financial ratios
Table 9: Mylan Inc.: key facts
Table 10: Mylan Inc.: key financials ($)
Table 11: Mylan Inc.: key financial ratios
Table 12: Sandoz International GmbH: key facts
Table 13: Teva Pharmaceutical Industries Limited: key facts
Table 14: Teva Pharmaceutical Industries Limited: key financials ($)
Table 15: Teva Pharmaceutical Industries Limited: key financial ratios
Table 16: United Kingdom size of population (million), 2011–15
Table 17: United Kingdom gdp (constant 2005 prices, $ billion), 2011–15
Table 18: United Kingdom gdp (current prices, $ billion), 2011–15
Table 19: United Kingdom inflation, 2011–15
Table 20: United Kingdom consumer price index (absolute), 2011–15
Table 21: United Kingdom exchange rate, 2011–15

LIST OF FIGURES

Figure 1: United Kingdom generics market value: $ billion, 2011–15(e)
Figure 2: United Kingdom generics market volume: % of total pharma volume, 2011–15(e)
Figure 3: United Kingdom generics market geography segmentation: % share, by value, 2015(e)
Figure 4: United Kingdom generics market value forecast: $ billion, 2015–20
Figure 5: United Kingdom generics market volume forecast: % of total pharma volume, 2015–20
Figure 6: Forces driving competition in the generics market in the United Kingdom, 2015
Figure 7: Drivers of buyer power in the generics market in the United Kingdom, 2015
Figure 8: Drivers of supplier power in the generics market in the United Kingdom, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2015
Figure 11: Drivers of degree of rivalry in the generics market in the United Kingdom, 2015
Figure 12: Allergan plc: revenues & profitability
Figure 13: Allergan plc: assets & liabilities
Figure 14: Mylan Inc.: revenues & profitability
Figure 15: Mylan Inc.: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Skip to top


Ask Your Question

Generics in the United Kingdom
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: